TY - JOUR
T1 - Varicella vaccination in Japan, South Korea, and Europe
AU - Sadzot-Delvaux, Catherine
AU - Rentier, Bernard
AU - Wutzler, Peter
AU - Asano, Yoshizo
AU - Suga, Sadao
AU - Yoshikawa, Tetsushi
AU - Plotkin, Stanley A.
N1 - Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Varicella Vaccine in the United States: A Decade of Prevention and the Way Forward,” sponsored by the Research Foundation for Microbial Diseases of Osaka University, GlaxoSmithKline Biologicals, the Sabin Vaccine Institute, the Centers for Disease Control and Prevention, and the March of Dimes.
PY - 2008/3/1
Y1 - 2008/3/1
N2 - The most extensive use of varicella vaccine has been in the United States and Canada, where it is universally recommended. However, a number of other countries now have recommendations for use of the vaccine, which has been expanding in Europe and Latin America. In this article, we review information concerning varicella vaccination in Japan, where the vaccine was first developed, and in South Korea and parts of Europe. Despite the worldwide availability of an efficient vaccine, varicella vaccination policy is highly variable from country to country. The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents.
AB - The most extensive use of varicella vaccine has been in the United States and Canada, where it is universally recommended. However, a number of other countries now have recommendations for use of the vaccine, which has been expanding in Europe and Latin America. In this article, we review information concerning varicella vaccination in Japan, where the vaccine was first developed, and in South Korea and parts of Europe. Despite the worldwide availability of an efficient vaccine, varicella vaccination policy is highly variable from country to country. The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents.
UR - http://www.scopus.com/inward/record.url?scp=42549157579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=42549157579&partnerID=8YFLogxK
U2 - 10.1086/522163
DO - 10.1086/522163
M3 - Article
C2 - 18419395
AN - SCOPUS:42549157579
VL - 197
SP - S185-S190
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - SUPPL. 2
ER -